Clinical trial
A Phase 2 Open-label Study of Setmelanotide in Patients With Prader-Willi Syndrome
NCT06772597 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Open-label Study of Setmelanotide in Patients With Prader-Willi Syndrome
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- March 4, 2025
- Completion date
- October 31, 2027
- Enrollment
- 18 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.